Citius Pharmaceuticals Stock Today
| CTXR Stock | USD 1.52 0.03 1.94% |
PerformanceVery Weak
| Odds Of DistressLow
|
Citius Pharmaceuticals is selling at 1.52 as of the 22nd of March 2025; that is 1.94 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.5. Citius Pharmaceuticals has less than a 10 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 22nd of December 2024 and ending today, the 22nd of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 6th of July 2017 | Category Healthcare | Classification Health Care |
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company has 8.59 M outstanding shares of which 540.14 K shares are currently shorted by private and institutional investors with about 3.24 trading days to cover. More on Citius Pharmaceuticals
Moving together with Citius Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Citius Stock Highlights
| President CEO, Director | Myron Holubiak | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsCitius Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Citius Pharmaceuticals' financial leverage. It provides some insight into what part of Citius Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Citius Pharmaceuticals (CTXR) is traded on NASDAQ Exchange in USA. It is located in 11 Commerce Drive, Cranford, NJ, United States, 07016 and employs 23 people. Citius Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.32 M. Citius Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 8.59 M outstanding shares of which 540.14 K shares are currently shorted by private and institutional investors with about 3.24 trading days to cover.
Citius Pharmaceuticals currently holds about 48.04 M in cash with (28.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33.
Check Citius Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Citius Pharmaceuticals is $13.32 Million. Citius Pharmaceuticals shows 5.73 percent of its outstanding shares held by insiders and 7.97 percent owned by other corporate entities. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Citius Ownership Details
Citius Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Tower Research Capital Llc | 2024-12-31 | 8.2 K | |
| Ifp Advisors, Llc | 2024-12-31 | 7.1 K | |
| Group One Trading, Lp | 2024-12-31 | 4.8 K | |
| Royal Bank Of Canada | 2024-12-31 | 4 K | |
| Sbi Securities Co Ltd | 2024-12-31 | 2.3 K | |
| Simplex Trading, Llc | 2024-12-31 | 1.7 K | |
| Fairscale Capital, Llc | 2024-12-31 | 366 | |
| Luminist Capital Llc | 2024-12-31 | 340 | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 318 | |
| Advisor Group Holdings, Inc. | 2024-09-30 | 931.8 K | |
| Vanguard Group Inc | 2024-12-31 | 257.6 K |
Citius Pharmaceuticals Historical Income Statement
Citius Stock Against Markets
Citius Pharmaceuticals Corporate Management
| Myron MD | Executive Officer | Profile | |
| Dhananjay Wadekar | Senior Strategy | Profile | |
| Catherine MS | Executive Affairs | Profile | |
| Nikolas Burlew | Executive Assurance | Profile | |
| Ilanit Allen | Vice Communications | Profile |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.